HD-OPM Archive
Hashtags

#clinicaltrials

3 posts

Lepodisiran siRNA cut Lp(a) by 93.9% at 400 mg in a 320-person NEJM trial

May 07, 2025 · Louis Nervegna ♥ 15 · 💬 1 Lp(a)

Luigi Fontana's summary of an NEJM trial of lepodisiran, an siRNA that blocks hepatic Lp(a) production. At the 400 mg dose Lp(a) fell by 93.9% placebo-adjusted, lasting up to a year, with only mild injection-site reactions. It offers a potential option for people with genetically high Lp(a) who cannot lower it with lifestyle or standard drugs.